The Department of Oncology has an opportunity for a Clinical Research Fellow to work on the Early Phase Cancer Trials Unit, headed by Professor Mark Middleton. The postholder will be working alongside staff in the Oxford NIHR Biomedical Research Centre, Oxford University Hospitals and the University of Oxford. The focus of this post includes the opportunity to engage in a translational research project under the supervision of a scientist in the Oxford Cancer Research Centre.
Cancer research at Oxford University is spread across the city with departments in the central Science Area, the Old Road Campus, the John Radcliffe Hospital, the Churchill Hospital and Commercial Science Parks. This combined expertise contributes to our efforts to increase cancer cure rates. The Cancer Research-UK Oxford Centre is committed to ensuring that the breadth and depth of this expertise is harnessed through multi-disciplinary collaborative projects.
We have an exciting opportunity for a Consortia Programmes Manager to oversee specific research programmes and projects administered by the Department of Oncology, including the CRUK and EPSRC Cancer Imaging Centre in Oxford and MRC SCORT programme. This is a challenging role to support the development and delivery of key strategic projects; developing, improving and implementing policy; committee servicing; and both written and oral communication.
An exciting new opportunity has arisen within S-CORT, a consortium recently funded by the Medical Research Council and Cancer Research-UK to further investigate stratification in colorectal cancer and to develop clinical stratifiers to aid clinical management.
This post will be located in the Bioinformatics Core in the Department of Oncology and the project will be overseen by the investigators: Professors Maughan (clinical), Tomlinson (genetics) and Holmes (statistics).
We have an exciting opportunity for a Postdoctoral Researcher to work in the laboratories of Dr Anne Kiltie and Professor Eleanor Stride. You will be part of two enthusiastic research teams investigating the role of DNA damage signaling and DNA repair. The primary aim of this post is to develop an encapsulated delivery method for chemotherapy drugs using micro/nanobubble technology for use in vivo, in an orthotopic bladder cancer model, in combination with ionising radiation.
Cong Li from the Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Shanghai 201203, China
Recent adaptation of the CRISPR/Cas9 bacterial system to facilitate manipulation of mammalian genomes has provided a real breakthrough for genome editing applications. Development of whole-genome CRISPR libraries with the aim of generating gene knockouts for every single coding sequence has allowed forward genetic screening in mammalian cells with unprecedented efficiency and versatility. CRISPR/Cas9 approaches, however, rely on phenotypes associated with loss-of-function mutations.